ClinicalTrials.gg
CompletedNCT02326220ODYSSEY ESCAPEUpdated May 1, 2020Results posted

Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy

A Phase 3 interventional study of Placebo and Alirocumab in Heterozygous Familial Hypercholesterolemia, sponsored by Regeneron Pharmaceuticals. Completed at 13 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-01.

Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 76 studies in Hyperlipoproteinemia Type II with a site in United States — 17 open to participants now, 18 under way, 6 of them phase 3. Hyperlipoproteinemia Type II · United States.

Enrollment
48th of 68
62 · median 163
Started
2015
with 1 other
Phase 3
30 of 76
5 open now
Registered
28th of 76
by date

Among the 76 studies in Hyperlipoproteinemia Type II with a site in United States, this one is the 48th largest by enrollment of the 68 interventional ones that give a count, is one of 2 that started in 2015, is one of 30 in phase 3, and was the 28th registered.

Hyperlipoproteinemia Type II

249 studies on the registry are indexed under Hyperlipoproteinemia Type II; 56 are open to participants now.

Browse Hyperlipoproteinemia Type II studies →

Open to participants now

17 of the 76 studies in Hyperlipoproteinemia Type II with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 36 Hyperlipoproteinemia Type II studies recruiting now, 17 (47%) set no upper age limit and 15 (42%) stop at 75 or younger; 17 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Hyperlipoproteinemia Type II with a site in United States, or all of them as a file.
02

Study summary

The primary objective of the study is to evaluate the effect of alirocumab 150 mg every 2 weeks (Q2W) in comparison with placebo on the frequency of low-density lipoprotein (LDL) apheresis treatments in participants with heterozygous familial hypercholesterolemia (HeFH) undergoing weekly or bi-weekly LDL apheresis therapy.

Read the detailed description

LDL apheresis removes low-density lipoproteins (LDL) that transport cholesterol in the plasma portion of the blood. This treatment is mainly used for familial hypercholesterolemia, but can be used in other rare diseases. Familial hypercholesterolemia (HeFH) is an inherited genetic condition that causes accumulation of cholesterol in the blood, which can lead to atherosclerosis and heart disease. This treatment is recommended for patients who do not respond to dietary and/or medication control of LDL cholesterol.

03

Conditions studied

  • Heterozygous Familial Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women ≥18 years of age at the time of the screening visit
  2. Diagnosis of HeFH (Heterozygous familial hypercholesterolemia)
  3. Currently undergoing LDL (low-density lipoprotein) apheresis therapy QW (weekly) or Q2W (every 2 weeks) or at least 8 weeks prior to the screening visit

Exclusion criteria

Exclusion Criteria:

  1. Homozygous FH (familial hypercholesterolemia)
  2. Background medical LMT (lipid-modifying therapy) (if applicable) that has not been stable for at least 8 weeks prior to the screening visit
  3. LDL apheresis schedule/ apheresis settings that have not been stable for at least 8 weeks prior to the screening visit
  4. An LDL apheresis schedule other than QW to Q2W
  5. Initiation of a new exercise program or exercise that has not remained stable within 8 weeks prior to the screening visit (week -2)
  6. Initiation of a new diet or a diet that has not been stable within 8 weeks prior to the screening visit (week -2)
  7. Use of nutraceuticals or over-the-counter therapies known to affect lipids, at a dose/amount that has not been stable for at least 8 weeks prior to the screening visit (week -2), or between the screening and randomization visit
  8. Presence of any uncontrolled endocrine disease known to influence serum lipids or lipoproteins
  9. Known history of a positive test for
  10. Use of any active drugs within 1 month or 5 half-lives of screening, whichever is longer
  11. Patients who have been treated with at least 1 dose of alirocumab or any other anti-PCSK9 monoclonal antibody in any other clinical studies
  12. Pregnant or breastfeeding women
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Placebo Q2W (Double Blind Period)

    Placebo (for alirocumab) subcutaneous (SC) injection Q2W up to Week 16.

    Drug: Placebo

  • Experimental
    Alirocumab 150 mg Q2W (Double Blind Period)

    Alirocumab 150 mg SC injection Q2W up to Week 16.

    Drug: Alirocumab

  • Experimental
    Alirocumab 150 Q2W (Open Label Treatment Period)

    Alirocumab 150 mg SC injection Q2W starting from Week 18 up to Week 76.

    Drug: Alirocumab

Interventions

  • DrugPlacebo
  • Also known as: REGN727, SAR236553, Praluent®

06

What researchers measure

Primary outcomes

  1. Change in Standardized Rate of Apheresis Treatments From Week 7 to Week 18

    Rate of apheresis treatments were normalized by the number of planned apheresis treatments according to each participant's established schedule at screening, week -10 to week -2. The normalized rate of apheresis was defined for each participant as the number of actual apheresis treatments received from week 7 to week 18 divided by the number of planned apheresis treatments per randomization strata at baseline (6 for Q2W and 12 for QW).

    Time frame: Week 7 to Week 18 (before start of open-label treatment)

Secondary outcomes

  1. Percent Change From Baseline in Calculated LDL-C (Pre-apheresis) at Week 6

    Adjusted Least-squares (LS) means and standard errors at Week 6 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 2 to Week 18 regardless of status on or off-treatment were used in the model (ITT analysis).

    Time frame: Baseline and at Week 6

  2. Change in Standardized Rate of Apheresis Treatments From Week 15 to Week 18

    Rate of apheresis treatments were normalized by the rate by the number of actual apheresis treatments according to received from week 15 to week 18 divided by the planned apheresis treatments per randomization strata at baseline (2 for Q2W and 4 for QW). Only legitimate apheresis treatment skipping per point-of-care LDL-C value is counted as "apheresis not occurred". Missing apheresis treatment information (any reason) from week 7 to week 18 is assigned an outcome of the apheresis treatment occurred at the visit (i.e. impute 1 apheresis treatment for that visit).

    Time frame: Week 15 up to Week 18 (before the start of open-label treatment dose)

  3. Percent Change From Baseline in Apolipoprotein B (Apo B) (Pre-apheresis) to Week 6

    Adjusted LS means and standard errors at Week 6 were obtained from MMRM to account for missing data. All available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).

    Time frame: From Baseline to Week 6

  4. Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) (Pre-apheresis) to Week 6

    Adjusted LS means and standard errors at Week 6 were obtained from MMRM to account for missing data. All available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).

    Time frame: From Baseline to Week 6

  5. Percent Change From Baseline in Total Cholesterol (Pre-apheresis) to Week 6

    Adjusted LS means and standard errors at Week 6 were obtained from MMRM to account for missing data. All available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).

    Time frame: From Baseline to Week 6

  6. Percent Change From Baseline in Apolipoprotein A (Apo A1) (Pre-apheresis) to Week 6

    Adjusted LS means and standard errors at Week 6 were obtained from MMRM to account for missing data. All available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).

    Time frame: From Baseline to Week 6

  7. Percentage of Participants With At Least (>=) 30% Reduction in Calculated LDL-C (Pre-apheresis) at Week 6

    Percentage of participants at Week 6 was obtained from a last observation carried forward (LOCF) model for handling of missing data. All available post-baseline data regardless of status on- or off-treatment were used in the model (ITT analysis).

    Time frame: From Baseline to Week 6

  8. Percentage of Participants With At Least (>=) 50% Reduction in Calculated LDL-C (Pre-apheresis) at Week 6

    Percentage of participants at Week 6 was obtained from LOCF model for handling of missing data. All available post-baseline data regardless of status on- or off-treatment were used in the model (ITT analysis).

    Time frame: From Baseline to Week 6

  9. Percent Change From Baseline in Calculated LDL-C (Pre-Apheresis) to Week 18

    Adjusted LS means and standard errors at Week 18 were obtained from MMRM to account for missing data. All available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).

    Time frame: From Baseline to Week 18

  10. Percent Change From Baseline in Apolipoprotein B (Apo B) (Pre-apheresis) to Week 18

    Adjusted LS means and standard errors at Week 18 were obtained from MMRM to account for missing data. All available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).

    Time frame: From Baseline to Week 18

  11. Percent Change From Baseline in Non-HDL-C (Pre-apheresis) to Week 18

    Adjusted LS means and standard errors at Week 18 were obtained from MMRM to account for missing data. All available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).

    Time frame: From Baseline to Week 18

  12. Percent Change From Baseline in Total Cholesterol (Pre-apheresis) to Week 18

    Adjusted LS means and standard errors at Week 18 were obtained from MMRM to account for missing data. All available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).

    Time frame: From Baseline to Week 18

  13. Percent Change From Baseline in Apo A1 (Pre-apheresis) to Week 18

    Adjusted LS means and standard errors at Week 18 were obtained from MMRM to account for missing data. All available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).

    Time frame: From Baseline to Week 18

  14. Percentage of Participants With At Least (>=) 30% Reduction in Calculated LDL-C (Pre-apheresis) at Week 18

    Percentage of participants at Week 18 was obtained from LOCF model for handling of missing data. All available post-baseline data regardless of status on- or off-treatment were used in the model (ITT analysis).

    Time frame: From Baseline to Week 18

  15. Percentage of Participants With At Least (>=) 50% Reduction in Calculated LDL-C (Pre-apheresis) at Week 18

    Percentage of participants at Week 18 was obtained from LOCF model for handling of missing data. All available post-baseline data regardless of status on- or off-treatment were used in the model (ITT analysis).

    Time frame: From Baseline to Week 18

  16. Change From Baseline in W-BQ22 (Well-being Questionnaire) Index Score at Week 18

    The W-BQ22 (well-being) questionnaire was a standardized and generic instrument used for measuring the impact of hypercholesterolemia and treatment on well-being of participants. The general well-being score was calculated as the sum of 22 questions in the W-BQ22 questionnaire (each question scored from 0 to 3 \[0 = not at all and 3 = all the time\]). Total score for 22 questions range from 0 to 66 \[0 = worst condition and 66 = best well-being condition).

    Time frame: From Baseline to Week 18

  17. Percent Change From Baseline in Lipoprotein (a) (Lp [a]) (Pre-apheresis) to Week 6

    Adjusted means and standard errors at Week 6 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).

    Time frame: From Baseline to Week 6

  18. Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) (Pre-apheresis) to Week 6

    Adjusted LS means and standard errors at Week 6 were obtained from MMRM to account for missing data. All available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).

    Time frame: From Baseline to Week 6

  19. Percent Change From Baseline in Triglyceride (TG) Levels (Pre-apheresis) to Week 6

    Adjusted means and standard errors at Week 6 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).

    Time frame: From Baseline to Week 6

  20. Percent Change From Baseline in Lp (a) (Pre-apheresis) to Week 18

    Adjusted means and standard errors at Week 18 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).

    Time frame: From Baseline to Week 18

  21. Percent Change From Baseline in HDL-C (Pre-apheresis) to Week 18

    Adjusted LS means and standard errors at Week 18 were obtained from MMRM to account for missing data. All available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).

    Time frame: From Baseline to Week 18

  22. Percent Change From Baseline in TG Levels (Pre-apheresis) to Week 18

    Adjusted means and standard errors at Week 18 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).

    Time frame: From Baseline to Week 18

07

Results

Posted May 1, 2020

Participant flow

The study was conducted in Germany and the United States between 09 Mar 2015 and 20 Apr 2016. A total of 76 participants were screened, of which 62 were enrolled and randomized in the study.

Double-blind Treatment Period
Participant flow — Double-blind Treatment Period
MilestonePlacebo Q2W (Double Blind Period)Alirocumab 150 mg Q2W (Double Blind Period)Alirocumab 150 Q2W (Open Label Treatment Period)
Started21410
Completed20370
Not completed140
Withdrew: Adverse event120
Withdrew: Protocol violation010
Withdrew: Withdrawal by subject010
Open-label Treatment Period
Participant flow — Open-label Treatment Period
MilestonePlacebo Q2W (Double Blind Period)Alirocumab 150 mg Q2W (Double Blind Period)Alirocumab 150 Q2W (Open Label Treatment Period)
Started0029
Completed0027
Not completed002
Withdrew: Withdrawal by subject001
Withdrew: Lost to follow-up001

Outcome measures

PrimaryChange in Standardized Rate of Apheresis Treatments From Week 7 to Week 18

Rate of apheresis treatments were normalized by the number of planned apheresis treatments according to each participant's established schedule at screening, week -10 to week -2. The normalized rate of apheresis was defined for each participant as the number of actual apheresis treatments received from week 7 to week 18 divided by the number of planned apheresis treatments per randomization strata at baseline (6 for Q2W and 12 for QW).

Time frame:
Week 7 to Week 18 (before start of open-label treatment)
Reported as:
Mean · Treatments
Change in Standardized Rate of Apheresis Treatments From Week 7 to Week 18
TreatmentsPlacebo Q2W (Double Blind Period)Alirocumab 150 mg Q2W (Double Blind Period)
Change in Standardized Rate of Apheresis Treatments From Week 7 to Week 180.806 ± 0.1910.128 ± 0.242
Statistical analysis
  • Placebo Q2W (Double Blind Period) vs Alirocumab 150 mg Q2W (Double Blind Period) · ANCOVA · p = < 0.0001 (Threshold for significance at 0.05 level.) · H-l estimate of median difference: 0.750 · 95% CI 0.667 to 0.833Alirocumab 150 mg Q2W (Double Blind Period) vs. Placebo Q2W (Double Blind Period)
SecondaryPercent Change From Baseline in Calculated LDL-C (Pre-apheresis) at Week 6

Adjusted Least-squares (LS) means and standard errors at Week 6 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 2 to Week 18 regardless of status on or off-treatment were used in the model (ITT analysis).

Time frame:
Baseline and at Week 6
Reported as:
Least squares mean · percent change in mmol/L
Percent Change From Baseline in Calculated LDL-C (Pre-apheresis) at Week 6
percent change in mmol/LPlacebo Q2W (Double Blind Period)Alirocumab 150 mg Q2W (Double Blind Period)
Percent Change From Baseline in Calculated LDL-C (Pre-apheresis) at Week 61.6 ± 3.1-53.7 ± 2.3
Statistical analysis
  • Placebo Q2W (Double Blind Period) vs Alirocumab 150 mg Q2W (Double Blind Period) · MMRM · p = < 0.0001 (Threshold for significance at 0.05 level.) · Least square (ls) mean difference: -55.3 · 95% CI -63.0 to -47.5Alirocumab 150 mg Q2W (Double Blind Period) vs. Placebo Q2W (Double Blind Period)
SecondaryChange in Standardized Rate of Apheresis Treatments From Week 15 to Week 18

Rate of apheresis treatments were normalized by the rate by the number of actual apheresis treatments according to received from week 15 to week 18 divided by the planned apheresis treatments per randomization strata at baseline (2 for Q2W and 4 for QW). Only legitimate apheresis treatment skipping per point-of-care LDL-C value is counted as "apheresis not occurred". Missing apheresis treatment information (any reason) from week 7 to week 18 is assigned an outcome of the apheresis treatment occurred at the visit (i.e. impute 1 apheresis treatment for that visit).

Time frame:
Week 15 up to Week 18 (before the start of open-label treatment dose)
Reported as:
Mean · Treatments
Change in Standardized Rate of Apheresis Treatments From Week 15 to Week 18
TreatmentsPlacebo Q2W (Double Blind Period)Alirocumab 150 mg Q2W (Double Blind Period)
Change in Standardized Rate of Apheresis Treatments From Week 15 to Week 180.774 ± 0.3150.165 ± 0.334
Statistical analysis
  • Placebo Q2W (Double Blind Period) vs Alirocumab 150 mg Q2W (Double Blind Period) · ANCOVA · p = <.0001 (Threshold for significance at 0.05 level.) · H-l estimate of median difference: 0.500 · 95% CI 0.500 to 1.000Alirocumab 150 mg Q2W (Double Blind Period) vs. Placebo Q2W (Double Blind Period)
SecondaryPercent Change From Baseline in Apolipoprotein B (Apo B) (Pre-apheresis) to Week 6

Adjusted LS means and standard errors at Week 6 were obtained from MMRM to account for missing data. All available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).

Time frame:
From Baseline to Week 6
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Apolipoprotein B (Apo B) (Pre-apheresis) to Week 6
Percent changePlacebo Q2W (Double Blind Period)Alirocumab 150 mg Q2W (Double Blind Period)
Percent Change From Baseline in Apolipoprotein B (Apo B) (Pre-apheresis) to Week 61.2 ± 3-42.8 ± 2.1
Statistical analysis
  • Placebo Q2W (Double Blind Period) vs Alirocumab 150 mg Q2W (Double Blind Period) · MMRM · p = < 0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -44 · 95% CI -51.3 to -36.6Alirocumab 150 mg Q2W (Double Blind Period) vs. Placebo Q2W (Double Blind Period)
SecondaryPercent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) (Pre-apheresis) to Week 6

Adjusted LS means and standard errors at Week 6 were obtained from MMRM to account for missing data. All available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).

Time frame:
From Baseline to Week 6
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) (Pre-apheresis) to Week 6
Percent changePlacebo Q2W (Double Blind Period)Alirocumab 150 mg Q2W (Double Blind Period)
Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) (Pre-apheresis) to Week 62.8 ± 2.9-47.1 ± 2.1
Statistical analysis
  • Placebo Q2W (Double Blind Period) vs Alirocumab 150 mg Q2W (Double Blind Period) · MMRM · p = < 0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -50 · 95% CI -57.3 to -42.7Alirocumab 150 mg Q2W (Double Blind Period) vs. Placebo Q2W (Double Blind Period)
SecondaryPercent Change From Baseline in Total Cholesterol (Pre-apheresis) to Week 6

Adjusted LS means and standard errors at Week 6 were obtained from MMRM to account for missing data. All available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).

Time frame:
From Baseline to Week 6
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Total Cholesterol (Pre-apheresis) to Week 6
Percent changePlacebo Q2W (Double Blind Period)Alirocumab 150 mg Q2W (Double Blind Period)
Percent Change From Baseline in Total Cholesterol (Pre-apheresis) to Week 63.1 ± 2.5-36.4 ± 1.8
Statistical analysis
  • Placebo Q2W (Double Blind Period) vs Alirocumab 150 mg Q2W (Double Blind Period) · MMRM · p = < 0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -39.4 · 95% CI -45.6 to -33.2Alirocumab 150 mg Q2W (Double Blind Period) vs. Placebo Q2W (Double Blind Period)
SecondaryPercent Change From Baseline in Apolipoprotein A (Apo A1) (Pre-apheresis) to Week 6

Adjusted LS means and standard errors at Week 6 were obtained from MMRM to account for missing data. All available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).

Time frame:
From Baseline to Week 6
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Apolipoprotein A (Apo A1) (Pre-apheresis) to Week 6
Percent changePlacebo Q2W (Double Blind Period)Alirocumab 150 mg Q2W (Double Blind Period)
Percent Change From Baseline in Apolipoprotein A (Apo A1) (Pre-apheresis) to Week 60 ± 3.34.2 ± 2.4
Statistical analysis
  • Placebo Q2W (Double Blind Period) vs Alirocumab 150 mg Q2W (Double Blind Period) · MMRM · p = 0.3012 (Threshold for significance at 0.05 level.) · Ls mean difference: 4.2 · 95% CI -3.9 to 12.3Alirocumab 150 mg Q2W (Double Blind Period) vs. Placebo Q2W (Double Blind Period)
SecondaryPercentage of Participants With At Least (>=) 30% Reduction in Calculated LDL-C (Pre-apheresis) at Week 6

Percentage of participants at Week 6 was obtained from a last observation carried forward (LOCF) model for handling of missing data. All available post-baseline data regardless of status on- or off-treatment were used in the model (ITT analysis).

Time frame:
From Baseline to Week 6
Reported as:
Number · percentage of participants
Percentage of Participants With At Least (>=) 30% Reduction in Calculated LDL-C (Pre-apheresis) at Week 6
percentage of participantsPlacebo Q2W (Double Blind Period)Alirocumab 150 mg Q2W (Double Blind Period)
Percentage of Participants With At Least (>=) 30% Reduction in Calculated LDL-C (Pre-apheresis) at Week 64.895.1
SecondaryPercentage of Participants With At Least (>=) 50% Reduction in Calculated LDL-C (Pre-apheresis) at Week 6

Percentage of participants at Week 6 was obtained from LOCF model for handling of missing data. All available post-baseline data regardless of status on- or off-treatment were used in the model (ITT analysis).

Time frame:
From Baseline to Week 6
Reported as:
Number · percentage of participants
Percentage of Participants With At Least (>=) 50% Reduction in Calculated LDL-C (Pre-apheresis) at Week 6
percentage of participantsPlacebo Q2W (Double Blind Period)Alirocumab 150 mg Q2W (Double Blind Period)
Percentage of Participants With At Least (>=) 50% Reduction in Calculated LDL-C (Pre-apheresis) at Week 6063.4
SecondaryPercent Change From Baseline in Calculated LDL-C (Pre-Apheresis) to Week 18

Adjusted LS means and standard errors at Week 18 were obtained from MMRM to account for missing data. All available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).

Time frame:
From Baseline to Week 18
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Calculated LDL-C (Pre-Apheresis) to Week 18
Percent changePlacebo Q2W (Double Blind Period)Alirocumab 150 mg Q2W (Double Blind Period)
Percent Change From Baseline in Calculated LDL-C (Pre-Apheresis) to Week 184 ± 6.2-42.3 ± 4.5
SecondaryPercent Change From Baseline in Apolipoprotein B (Apo B) (Pre-apheresis) to Week 18

Adjusted LS means and standard errors at Week 18 were obtained from MMRM to account for missing data. All available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).

Time frame:
From Baseline to Week 18
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein B (Apo B) (Pre-apheresis) to Week 18
percent changePlacebo Q2W (Double Blind Period)Alirocumab 150 mg Q2W (Double Blind Period)
Percent Change From Baseline in Apolipoprotein B (Apo B) (Pre-apheresis) to Week 181.7 ± 4.8-33.8 ± 3.5
SecondaryPercent Change From Baseline in Non-HDL-C (Pre-apheresis) to Week 18

Adjusted LS means and standard errors at Week 18 were obtained from MMRM to account for missing data. All available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).

Time frame:
From Baseline to Week 18
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Non-HDL-C (Pre-apheresis) to Week 18
Percent changePlacebo Q2W (Double Blind Period)Alirocumab 150 mg Q2W (Double Blind Period)
Percent Change From Baseline in Non-HDL-C (Pre-apheresis) to Week 184.7 ± 5.6-35.7 ± 4.1
SecondaryPercent Change From Baseline in Total Cholesterol (Pre-apheresis) to Week 18

Adjusted LS means and standard errors at Week 18 were obtained from MMRM to account for missing data. All available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).

Time frame:
From Baseline to Week 18
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Total Cholesterol (Pre-apheresis) to Week 18
Percent changePlacebo Q2W (Double Blind Period)Alirocumab 150 mg Q2W (Double Blind Period)
Percent Change From Baseline in Total Cholesterol (Pre-apheresis) to Week 184.7 ± 4.7-27.1 ± 3.4
SecondaryPercent Change From Baseline in Apo A1 (Pre-apheresis) to Week 18

Adjusted LS means and standard errors at Week 18 were obtained from MMRM to account for missing data. All available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).

Time frame:
From Baseline to Week 18
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Apo A1 (Pre-apheresis) to Week 18
Percent changePlacebo Q2W (Double Blind Period)Alirocumab 150 mg Q2W (Double Blind Period)
Percent Change From Baseline in Apo A1 (Pre-apheresis) to Week 18-0.7 ± 3.47.8 ± 2.4
SecondaryPercentage of Participants With At Least (>=) 30% Reduction in Calculated LDL-C (Pre-apheresis) at Week 18

Percentage of participants at Week 18 was obtained from LOCF model for handling of missing data. All available post-baseline data regardless of status on- or off-treatment were used in the model (ITT analysis).

Time frame:
From Baseline to Week 18
Reported as:
Number · percentage of participants
Percentage of Participants With At Least (>=) 30% Reduction in Calculated LDL-C (Pre-apheresis) at Week 18
percentage of participantsPlacebo Q2W (Double Blind Period)Alirocumab 150 mg Q2W (Double Blind Period)
Percentage of Participants With At Least (>=) 30% Reduction in Calculated LDL-C (Pre-apheresis) at Week 18065.9
SecondaryPercentage of Participants With At Least (>=) 50% Reduction in Calculated LDL-C (Pre-apheresis) at Week 18

Percentage of participants at Week 18 was obtained from LOCF model for handling of missing data. All available post-baseline data regardless of status on- or off-treatment were used in the model (ITT analysis).

Time frame:
From Baseline to Week 18
Reported as:
Number · percentage of participants
Percentage of Participants With At Least (>=) 50% Reduction in Calculated LDL-C (Pre-apheresis) at Week 18
percentage of participantsPlacebo Q2W (Double Blind Period)Alirocumab 150 mg Q2W (Double Blind Period)
Percentage of Participants With At Least (>=) 50% Reduction in Calculated LDL-C (Pre-apheresis) at Week 18043.9
SecondaryChange From Baseline in W-BQ22 (Well-being Questionnaire) Index Score at Week 18

The W-BQ22 (well-being) questionnaire was a standardized and generic instrument used for measuring the impact of hypercholesterolemia and treatment on well-being of participants. The general well-being score was calculated as the sum of 22 questions in the W-BQ22 questionnaire (each question scored from 0 to 3 \[0 = not at all and 3 = all the time\]). Total score for 22 questions range from 0 to 66 \[0 = worst condition and 66 = best well-being condition).

Time frame:
From Baseline to Week 18
Reported as:
Least squares mean · scores on a scale
Change From Baseline in W-BQ22 (Well-being Questionnaire) Index Score at Week 18
scores on a scalePlacebo Q2W (Double Blind Period)Alirocumab 150 mg Q2W (Double Blind Period)
Change From Baseline in W-BQ22 (Well-being Questionnaire) Index Score at Week 18-1.43 ± 1.4410.91 ± 1.04
SecondaryPercent Change From Baseline in Lipoprotein (a) (Lp [a]) (Pre-apheresis) to Week 6

Adjusted means and standard errors at Week 6 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).

Time frame:
From Baseline to Week 6
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Lipoprotein (a) (Lp [a]) (Pre-apheresis) to Week 6
percent changePlacebo Q2W (Double Blind Period)Alirocumab 150 mg Q2W (Double Blind Period)
Percent Change From Baseline in Lipoprotein (a) (Lp [a]) (Pre-apheresis) to Week 6-4 ± 5.1-18.1 ± 3.7
SecondaryPercent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) (Pre-apheresis) to Week 6

Adjusted LS means and standard errors at Week 6 were obtained from MMRM to account for missing data. All available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).

Time frame:
From Baseline to Week 6
Reported as:
Least squares mean · percent change
Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) (Pre-apheresis) to Week 6
percent changePlacebo Q2W (Double Blind Period)Alirocumab 150 mg Q2W (Double Blind Period)
Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) (Pre-apheresis) to Week 64 ± 3.49.3 ± 2.4
SecondaryPercent Change From Baseline in Triglyceride (TG) Levels (Pre-apheresis) to Week 6

Adjusted means and standard errors at Week 6 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).

Time frame:
From Baseline to Week 6
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Triglyceride (TG) Levels (Pre-apheresis) to Week 6
percent changePlacebo Q2W (Double Blind Period)Alirocumab 150 mg Q2W (Double Blind Period)
Percent Change From Baseline in Triglyceride (TG) Levels (Pre-apheresis) to Week 63 ± 5.6-12.9 ± 4
SecondaryPercent Change From Baseline in Lp (a) (Pre-apheresis) to Week 18

Adjusted means and standard errors at Week 18 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).

Time frame:
From Baseline to Week 18
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Lp (a) (Pre-apheresis) to Week 18
Percent changePlacebo Q2W (Double Blind Period)Alirocumab 150 mg Q2W (Double Blind Period)
Percent Change From Baseline in Lp (a) (Pre-apheresis) to Week 18-1.2 ± 8-6.1 ± 5.9
SecondaryPercent Change From Baseline in HDL-C (Pre-apheresis) to Week 18

Adjusted LS means and standard errors at Week 18 were obtained from MMRM to account for missing data. All available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).

Time frame:
From Baseline to Week 18
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in HDL-C (Pre-apheresis) to Week 18
Percent changePlacebo Q2W (Double Blind Period)Alirocumab 150 mg Q2W (Double Blind Period)
Percent Change From Baseline in HDL-C (Pre-apheresis) to Week 182.4 ± 510.9 ± 3.6
SecondaryPercent Change From Baseline in TG Levels (Pre-apheresis) to Week 18

Adjusted means and standard errors at Week 18 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 2 (pre-apheresis) to Week 18 (pre-apheresis) regardless of status on- or off-treatment were used in the model (ITT analysis).

Time frame:
From Baseline to Week 18
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in TG Levels (Pre-apheresis) to Week 18
Percent changePlacebo Q2W (Double Blind Period)Alirocumab 150 mg Q2W (Double Blind Period)
Percent Change From Baseline in TG Levels (Pre-apheresis) to Week 184.1 ± 7.9-2.4 ± 5.8

Adverse events

Collected over All Adverse Events (AEs) were collected from signature of the informed consent form up to the final study end visit (maximum duration: 46 weeks) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Q2W (Double Blind Period)0/21 (0%)2/21 (9.5%)10/21 (47.6%)
Alirocumab 150 Q2W (Double Blind Period)0/41 (0%)4/41 (9.8%)22/41 (53.7%)
Alirocumab 150 Q2W (Open Label Treatment Period)0/29 (0%)1/29 (3.4%)2/29 (6.9%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventPlacebo Q2W (Double Blind Period)Alirocumab 150 Q2W (Double Blind Period)Alirocumab 150 Q2W (Open Label Treatment Period)
Acute myocardial infarctionCardiac disorders0/212/410/29
Angina pectorisCardiac disorders1/210/410/29
Sinus bradycardiaCardiac disorders1/210/410/29
Shunt thrombosisInjury, poisoning and procedural complications1/210/410/29
Myocardial ischaemiaCardiac disorders0/210/411/29
Peripheral artery restenosisInjury, poisoning and procedural complications0/210/411/29
Angina unstableCardiac disorders0/211/410/29
Aortic valve stenosisCardiac disorders0/211/410/29
Cardiac failure congestiveCardiac disorders0/211/410/29
PneumoniaInfections and infestations0/211/410/29
Most frequent other events
Showing 10 of 11
Most frequent other events
EventPlacebo Q2W (Double Blind Period)Alirocumab 150 Q2W (Double Blind Period)Alirocumab 150 Q2W (Open Label Treatment Period)
Upper respiratory tract infectionInfections and infestations4/213/410/29
FatigueGeneral disorders2/216/410/29
NauseaGastrointestinal disorders3/212/410/29
MyalgiaMusculoskeletal and connective tissue disorders1/215/410/29
DiarrhoeaGastrointestinal disorders0/214/410/29
NasopharyngitisInfections and infestations2/214/411/29
PalpitationsCardiac disorders2/210/410/29
ArthralgiaMusculoskeletal and connective tissue disorders2/213/410/29
Back painMusculoskeletal and connective tissue disorders2/212/410/29
HeadacheNervous system disorders2/213/410/29

Baseline characteristics

Analysis was performed on randomized population.

Age, Continuous
Age, Continuous(years)Placebo Q2W (Double Blind Period)Alirocumab 150 mg Q2W (Double Blind Period)Total
Mean57 ± 10.559.5 ± 9.258.7 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Q2W (Double Blind Period)Alirocumab 150 mg Q2W (Double Blind Period)Total
Female111526
Male102636
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo Q2W (Double Blind Period)Alirocumab 150 mg Q2W (Double Blind Period)Total
Hispanic or Latino000
Not Hispanic or Latino214162
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo Q2W (Double Blind Period)Alirocumab 150 mg Q2W (Double Blind Period)Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American022
White213960
More than one race000
Unknown or Not Reported000
Frequency in which participants are undergoing LDL apheresis
Frequency in which participants are undergoing LDL apheresis(Treatments)Placebo Q2W (Double Blind Period)Alirocumab 150 mg Q2W (Double Blind Period)Total
Every week91827
Every 2 weeks122335
Calculated low-density lipoprotein cholesterol (LDL-C)
Calculated low-density lipoprotein cholesterol (LDL-C)(mg/dL)Placebo Q2W (Double Blind Period)Alirocumab 150 mg Q2W (Double Blind Period)Total
Mean191.6 ± 68.9175.1 ± 54.6180.7 ± 59.7
Measured LDL-C
Measured LDL-C(mg/dL)Placebo Q2W (Double Blind Period)Alirocumab 150 mg Q2W (Double Blind Period)Total
Mean195.0 ± 66.9174.0 ± 51.4181.1 ± 57.4
Non-high-density lipoprotein cholesterol (HDL-C)
Non-high-density lipoprotein cholesterol (HDL-C)(mg/dL)Placebo Q2W (Double Blind Period)Alirocumab 150 mg Q2W (Double Blind Period)Total
Mean224.5 ± 68.0210.3 ± 62.8215.1 ± 64.4

6 further baseline measures are reported on the registry.

08

Study locations

13 sites
  • Aurora, Colorado, United States
  • Hartford, Connecticut, United States
  • Kansas City, Kansas, United States
  • Scarborough, Maine, United States
  • Rochester, Minnesota, United States
  • Portland, Oregon, United States
  • Philadelphia, Pennsylvania, United States
  • Dresden, Sachsen, Germany
  • Berlin, Germany
  • Göttingen, Germany
  • Muenchen (2 locations), Germany
  • Passau, Germany
  • Rostock, Germany
09

References and documents

Publications

  • Moriarty PM, Parhofer KG, Babirak SP, Cornier MA, Duell PB, Hohenstein B, Leebmann J, Ramlow W, Schettler V, Simha V, Steinhagen-Thiessen E, Thompson PD, Vogt A, von Stritzky B, Du Y, Manvelian G. Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. Eur Heart J. 2016 Dec 21;37(48):3588-3595. doi: 10.1093/eurheartj/ehw388. Epub 2016 Aug 29. PubMed 27572070 ↗
  • Moriarty PM, Parhofer KG, Babirak SP, deGoma E, Duell PB, Hohenstein B, Ramlow W, Simha V, Steinhagen-Thiessen E, Thompson PD, Vogt A, von Stritzky B, Du Y, Manvelian G. Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: Rationale and design of the ODYSSEY ESCAPE trial. J Clin Lipidol. 2016 May-Jun;10(3):627-34. doi: 10.1016/j.jacl.2016.02.003. Epub 2016 Feb 18. PubMed 27206951 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2015 to primary completion in Jan 2016, 10 months.

Results were first posted in May 2020, 4 years 3 months after primary completion. A results delay was requested in Jan 2017.

Of 29 industry-sponsored phase 3 interventional studies under Hyperlipoproteinemia Type II, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 34. This study's 10 months is below that.

Counting every sponsor, half of 33 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2014
First posted
Dec 29, 2014
StartActual
Mar 31, 2015
Primary completionActual
Jan 31, 2016
CompletionActual
Apr 30, 2016
Results delay requested
Jan 20, 2017
Results first posted
May 1, 2020
Last update
May 1, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02326220
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Dec 29, 2014
Start date
Mar 31, 2015
Primary completion
Jan 31, 2016
Completion
Apr 30, 2016
Results posted
May 1, 2020
Last update
May 1, 2020

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alirocumab

Start the discussion